Clinical Trial: ECOG-ACRIN E1912

ECOG-ACRIN E1912

Status: Closed

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

E1912 closed to accrual effective June 9, 2016 at 5:00 pm ET.